Acquired mutations or compensatory activation of downstream pathways (e.g., PI3K, PTEN, Met, or Ras) are some of the main resistance mechanisms for EGFR inhibitors used in HNSCC treatment [15]. Here, PTEN is linked to head and neck squamous cell carcinoma.